{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:52:08Z","timestamp":1790697128777,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006282","name":"Koning Boudewijnstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Espa\u00f1a Ministerio de Ciencia Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["667751"],"award-info":[{"award-number":["667751"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["PID2020-113864RB-100"],"award-info":[{"award-number":["PID2020-113864RB-100"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2021 SGR 01012"],"award-info":[{"award-number":["2021 SGR 01012"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003741","name":"Instituci\u00f3 Catalana de Recerca i Estudis Avan\u00e7ats","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003741","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013941","name":"CIBERDEM","doi-asserted-by":"publisher","award":["CB07\/08\/0037"],"award-info":[{"award-number":["CB07\/08\/0037"]}],"id":[{"id":"10.13039\/501100013941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["FPU2014-FPU14\/05268"],"award-info":[{"award-number":["FPU2014-FPU14\/05268"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.molmet.2024.101899","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T02:57:49Z","timestamp":1707533869000},"page":"101899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy"],"prefix":"10.1016","volume":"81","author":[{"given":"Sergio","family":"Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bertolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Ja\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pujol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Vil\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Sacristan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Barbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ronzitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad","family":"El Andari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warut","family":"Tulalamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quang Hong","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Ruberte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"VandenDriessche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinee K.","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mingozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7705-5515","authenticated-orcid":false,"given":"Fatima","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmet.2024.101899_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.molmet.2024.101899_bib2","doi-asserted-by":"crossref","DOI":"10.1097\/NEN.0b013e3181815994","article-title":"Temporal neuropathologic and behavioral phenotype of 6 neo\/6 neo Pompe pisease mice","volume":"67","author":"Sidman","year":"2008","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"23","key":"10.1016\/j.molmet.2024.101899_bib3","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"10.1016\/j.molmet.2024.101899_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.21037\/atm.2019.04.49","article-title":"An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond","volume":"7","author":"Korlimarla","year":"2019","journal-title":"Ann Transl Med"},{"issue":"11","key":"10.1016\/j.molmet.2024.101899_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11940-022-00736-1","article-title":"Pompe disease: a clinical, diagnostic, and therapeutic overview","volume":"24","author":"Stevens","year":"2022","journal-title":"Curr Treat Options Neurol"},{"issue":"13","key":"10.1016\/j.molmet.2024.101899_bib6","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2019.04.67","article-title":"Progress and challenges of gene therapy for Pompe disease","volume":"7","author":"Ronzitti","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.molmet.2024.101899_bib7","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2019.109","article-title":"Gene therapy for pompe disease: the time is now","author":"Colella","year":"2019","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.molmet.2024.101899_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020302","article-title":"Gene therapy developments for pompe disease","author":"Unnisa","year":"2022","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.molmet.2024.101899_bib9","doi-asserted-by":"crossref","DOI":"10.1006\/mthe.2002.0580","article-title":"Correction of the enzymatic and functional deficits in a model of pompe disease using adeno-associated virus vectors","volume":"5","author":"Fraites","year":"2002","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.molmet.2024.101899_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2005.01.012","article-title":"Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter","volume":"11","author":"Sun","year":"2005","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.molmet.2024.101899_bib11","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/mt.2009.305","article-title":"Gel-mediated delivery of AAV1 vectors corrects ventilatory function in pompe mice with established disease","volume":"18","author":"Mah","year":"2010","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.molmet.2024.101899_bib12","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: from basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"418","key":"10.1016\/j.molmet.2024.101899_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam6375","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase","volume":"9","author":"Puzzo","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.molmet.2024.101899_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2018.11.002","article-title":"AAV gene transfer with tandem promoter design prevents anti-transgene immunity and provides persistent efficacy in neonate pompe mice","volume":"12","author":"Colella","year":"2019","journal-title":"Molecular Therapy - Methods and Clinical Development"},{"key":"10.1016\/j.molmet.2024.101899_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103052","article-title":"Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects","volume":"61","author":"Colella","year":"2020","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.molmet.2024.101899_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2020.05.025","article-title":"Rescue of advanced pompe disease in mice with hepatic expression of secretable acid \u03b1-glucosidase","volume":"28","author":"Cagin","year":"2020","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26744-4","article-title":"Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates","volume":"12","author":"Costa-Verdera","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2004.10.004","article-title":"Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II","volume":"11","author":"Sun","year":"2005","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.molmet.2024.101899_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2008.133","article-title":"Correction of multiple striated muscles in murine pompe disease through adeno-associated virus-mediated gene therapy","volume":"16","author":"Sun","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.molmet.2024.101899_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.7","article-title":"Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice","volume":"2","author":"Falk","year":"2015","journal-title":"Molecular Therapy - Methods and Clinical Development"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib21","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2018.016","article-title":"Systemic delivery of AAVB1-GAA clears glycogen and prolongs survival in a mouse model of pompe disease","volume":"30","author":"Keeler","year":"2019","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.molmet.2024.101899_bib22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.omtm.2019.01.006","article-title":"Intravenous injection of an AAV-PHP.B vector encoding human acid \u03b1-glucosidase rescues both muscle and CNS defects in murine pompe disease","volume":"12","author":"Lim","year":"2019","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib23","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202113968","article-title":"Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity","volume":"14","author":"Eggers","year":"2022","journal-title":"EMBO Mol Med"},{"issue":"5","key":"10.1016\/j.molmet.2024.101899_bib24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/hum.2011.183","article-title":"Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector","volume":"23","author":"Wang","year":"2012","journal-title":"Hum Gene Ther"},{"issue":"9","key":"10.1016\/j.molmet.2024.101899_bib25","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2013.233","article-title":"Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar syndrome","volume":"25","author":"Bortolussi","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.molmet.2024.101899_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/14712598.2020.1817375","article-title":"Liver-directed gene-based therapies for inborn errors of metabolism","author":"Piccolo","year":"2021","journal-title":"Expet Opin Biol Ther"},{"issue":"4","key":"10.1016\/j.molmet.2024.101899_bib27","first-page":"503","article-title":"INCEPTUS natural history, run-in study for gene replacement clinical trial in X-linked myotubular myopathy","volume":"9","author":"Dowling","year":"2022","journal-title":"J\u00a0Neuromuscul Dis"},{"issue":"3\u20134","key":"10.1016\/j.molmet.2024.101899_bib28","article-title":"Distinct transduction of muscle tissue in mice after systemic delivery of AAVpo1 vectors","volume":"27","author":"Tulalamba","year":"2020","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19230-w","article-title":"Identification of a myotropic AAV by massively parallel in\u00a0vivo evaluation of barcoded capsid variants","volume":"11","author":"Weinmann","year":"2020","journal-title":"Nat Commun"},{"issue":"19","key":"10.1016\/j.molmet.2024.101899_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"issue":"38","key":"10.1016\/j.molmet.2024.101899_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn4704","article-title":"Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders","volume":"8","author":"El Andari","year":"2022","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-08283-7","article-title":"Next-generation muscle-directed gene therapy by in silico vector design","volume":"10","author":"Sarcar","year":"2019","journal-title":"Nat Commun"},{"issue":"30","key":"10.1016\/j.molmet.2024.101899_bib33","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid \u03b1-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/hmg\/7.1.53","article-title":"Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease","volume":"7","author":"Bijvoet","year":"1998","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.molmet.2024.101899_bib35","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/(SICI)1096-9896(199911)189:3<416::AID-PATH445>3.0.CO;2-6","article-title":"Pathological features of glycogen storage disease type II highlighted in the knockout mouse model","volume":"189","author":"Bijvoet","year":"1999","journal-title":"J\u00a0Pathol"},{"issue":"12","key":"10.1016\/j.molmet.2024.101899_bib36","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/hmg\/8.12.2145","article-title":"Human acid -glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II","volume":"8","author":"Bijvoet","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"4\u20135","key":"10.1016\/j.molmet.2024.101899_bib37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0960-8966(99)00117-0","article-title":"Modulation of disease severity in mice with targeted disruption of the acid \u03b1-glucosidase gene","volume":"10","author":"Raben","year":"2000","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.molmet.2024.101899_bib38","doi-asserted-by":"crossref","DOI":"10.1089\/humc.2014.2514","article-title":"Phase I\/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with pompe disease","volume":"25","author":"Byrne","year":"2014","journal-title":"Human Gene Therapy Clinical Development"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib39","article-title":"CRISPR-Cas9 generated Pompe knock-in murine model exhibits early-onset hypertrophic cardiomyopathy and skeletal muscle weakness","volume":"10","author":"Huang","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25914-8","article-title":"CRISPR-mediated generation and characterization of a Gaa homozygous c.1935C>A (p.D645E) Pompe disease knock-in mouse model recapitulating human infantile onset-Pompe disease","volume":"12","author":"Kan","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.molmet.2024.101899_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/gt.2009.157","article-title":"High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency","volume":"17","author":"Ayuso","year":"2010","journal-title":"Gene Ther"},{"issue":"2","key":"10.1016\/j.molmet.2024.101899_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41366-020-00700-6","article-title":"BMP7 overexpression in adipose tissue induces white adipogenesis and improves insulin sensitivity in ob\/ob mice","volume":"45","author":"Casana","year":"2021","journal-title":"Int J Obes"},{"issue":"11","key":"10.1016\/j.molmet.2024.101899_bib43","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-010-1840-7","article-title":"Chronically increased glucose uptake by adipose tissue leads to lactate production and improved insulin sensitivity rather than obesity in the mouse","volume":"53","author":"Mu\u00f1oz","year":"2010","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.molmet.2024.101899_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2011.220","article-title":"Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice","volume":"20","author":"Ruzo","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.molmet.2024.101899_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/nmeth.3408","article-title":"Off-target mutations are rare in Cas9-modified mice","author":"Iyer","year":"2015","journal-title":"Nat Methods"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib46","article-title":"Off- and on-target effects of genome editing in mouse embryos","volume":"65","author":"Ayabe","year":"2019","journal-title":"J\u00a0Reprod Dev"},{"issue":"5","key":"10.1016\/j.molmet.2024.101899_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A\u00a0retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J\u00a0Pediatr"},{"issue":"12","key":"10.1016\/j.molmet.2024.101899_bib48","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab Invest"},{"issue":"2","key":"10.1016\/j.molmet.2024.101899_bib49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.nmd.2016.10.010","article-title":"Quantification of muscle pathology in infantile Pompe disease","volume":"27","author":"Sch\u00e4nzer","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1016\/j.molmet.2024.101899_bib50","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/mus.10381","article-title":"Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy","volume":"27","author":"Winkel","year":"2003","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1750-1172-8-90","article-title":"Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy","volume":"8","author":"Prater","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.molmet.2024.101899_bib52","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.3390\/ijms22062850","article-title":"Muscle proteomic profile before and after enzyme replacement therapy in late-onset pompe disease","volume":"22","author":"Moriggi","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib53","article-title":"Glycogen storage disease type II: clinical overview","volume":"26","author":"Di Rocco","year":"2007","journal-title":"Acta Myol"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2005.10.211","article-title":"Molecular cloning and characterization of rat LC3A and LC3B - two novel markers of autophagosome","volume":"339","author":"Wu","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.molmet.2024.101899_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/path.2697","article-title":"Autophagy: cellular and molecular mechanisms","author":"Glick","year":"2010","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.molmet.2024.101899_bib56","doi-asserted-by":"crossref","DOI":"10.1186\/s11658-016-0031-z","article-title":"p62 links the autophagy pathway and the ubiqutin-proteasome system upon ubiquitinated protein degradation","author":"Liu","year":"2016","journal-title":"Cell Mol Biol Lett"},{"issue":"5939","key":"10.1016\/j.molmet.2024.101899_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/science.1174447","article-title":"A\u00a0gene network regulating lysosomal biogenesis and function","volume":"325","author":"Sardiello","year":"2009","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.molmet.2024.101899_bib58","article-title":"Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIIC","volume":"9","author":"Marc\u00f2","year":"2016","journal-title":"DMM Disease Models and Mechanisms"},{"issue":"2","key":"10.1016\/j.molmet.2024.101899_bib59","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1067\/mpd.2000.107112","article-title":"Identification of two subtypes of infantile acid maltase deficiency","volume":"137","author":"Slonim","year":"2000","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.molmet.2024.101899_bib60","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.molmet.2024.101899_bib61","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/01.GIM.0000154301.76619.5C","article-title":"Infantile onset Pompe disease: a report of physician narratives from an epidemiologic study","volume":"7","author":"Marsden","year":"2005","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.molmet.2024.101899_bib62","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/biomedicines9050446","article-title":"Murine models of lysosomal storage diseases exhibit differences in brain protein aggregation and neuroinflammation","volume":"9","author":"Clarke","year":"2021","journal-title":"Biomedicines"},{"issue":"6982","key":"10.1016\/j.molmet.2024.101899_bib63","article-title":"Genome sequence of the Brown Norway rat yields insights into mammalian evolution","volume":"428","author":"Gibbs","year":"2004","journal-title":"Nature"},{"issue":"5\u20136","key":"10.1016\/j.molmet.2024.101899_bib64","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1242\/dmm.002733","volume":"2","author":"Iannaccone","year":"2009","journal-title":"Rats! Disease Models & Mechanisms"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/sj.mt.6300325","article-title":"Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle","volume":"16","author":"Tessitore","year":"2008","journal-title":"Mol Ther"},{"issue":"10","key":"10.1016\/j.molmet.2024.101899_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110371","article-title":"Characterization of dystrophin deficient rats: a new model for duchenne muscular dystrophy","volume":"9","author":"Larcher","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.molmet.2024.101899_bib67","article-title":"Increased trabecular bone and improved biomechanics in an osteocalcin-null rat model created by CRISPR\/Cas9 technology","volume":"9","author":"Lambert","year":"2016","journal-title":"DMM Disease Models and Mechanisms"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25697-y","article-title":"Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy","volume":"12","author":"Bertolin","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.molmet.2024.101899_bib69","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-1-0716-3036-5_20","article-title":"In\u00a0vivo modeling of skeletal muscle diseases using the CRISPR\/Cas9 system in rats","volume":"2640","author":"Nakamura","year":"2023","journal-title":"Methods Mol Biol"},{"issue":"5","key":"10.1016\/j.molmet.2024.101899_bib70","first-page":"392","article-title":"More expansive gene transfer to the rat CNS: AAV PHP.EB vector dose\u2013response and comparison to AAV PHP","volume":"25","author":"Dayton","year":"2018","journal-title":"B.\u00a0Gene Therapy"},{"key":"10.1016\/j.molmet.2024.101899_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.36","article-title":"AAV9 supports wide-scale transduction of the CNS and TDP-43 disease modeling in adult rats","volume":"2","author":"Jackson","year":"2015","journal-title":"Molecular Therapy - Methods Clinical Develop"},{"issue":"13","key":"10.1016\/j.molmet.2024.101899_bib72","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-09-382317","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.molmet.2024.101899_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/gt.2012.43","article-title":"Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPL S447X) gene therapy for lipoprotein lipase deficiency: an open-label trial","volume":"20","author":"Gaudet","year":"2013","journal-title":"Gene Ther"},{"issue":"21","key":"10.1016\/j.molmet.2024.101899_bib74","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"10045","key":"10.1016\/j.molmet.2024.101899_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)30371-3","article-title":"Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial","volume":"388","author":"Bennett","year":"2016","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.molmet.2024.101899_bib76","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.molmet.2024.101899_bib77","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2019.217","article-title":"In\u00a0vivo gene therapy for mucopolysaccharidosis type III (sanfilippo syndrome): a new treatment Horizon","author":"Marc\u00f3","year":"2019","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.molmet.2024.101899_bib78","doi-asserted-by":"crossref","DOI":"10.1089\/humc.2017.146","article-title":"Safety of intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by pompe disease","volume":"28","author":"Corti","year":"2017","journal-title":"Human Gene Therapy Clinical Develop"},{"issue":"15","key":"10.1016\/j.molmet.2024.101899_bib79","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.75.15.6969-6976.2001","article-title":"Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in\u00a0vivo","volume":"75","author":"Nakai","year":"2001","journal-title":"J\u00a0Virol"},{"issue":"11","key":"10.1016\/j.molmet.2024.101899_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2011.151","article-title":"AAV8-mediated hepatic gene transfer in infant rhesus monkeys (macaca mulatta)","volume":"19","author":"Wang","year":"2011","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.molmet.2024.101899_bib81","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2011.183","article-title":"Hepatic gene transfer in Neonatal mice by Adeno-associated virus serotype 8 vector","volume":"23","author":"Wang","year":"2012","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.1016\/j.molmet.2024.101899_bib82","doi-asserted-by":"crossref","DOI":"10.1089\/humc.2015.068","article-title":"Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in pompe disease: preclinical to clinical planning","volume":"26","author":"Corti","year":"2015","journal-title":"Human Gene Therapy Clinical Develop"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.molmet.2024.101899_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in\u00a0vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.molmet.2024.101899_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther"},{"issue":"12","key":"10.1016\/j.molmet.2024.101899_bib86","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1242\/dev.01169","article-title":"Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: pompe disease","volume":"131","author":"Rucker","year":"2004","journal-title":"Development"},{"issue":"18","key":"10.1016\/j.molmet.2024.101899_bib87","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/sj.gt.3302550","article-title":"Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors","volume":"12","author":"Mah","year":"2005","journal-title":"Gene Ther"},{"issue":"3","key":"10.1016\/j.molmet.2024.101899_bib88","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.mt.6300100","article-title":"Physiological correction of pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors","volume":"15","author":"Mah","year":"2007","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.molmet.2024.101899_bib89","doi-asserted-by":"crossref","DOI":"10.1089\/humc.2016.119","article-title":"Transfer of therapeutic genes into fetal rhesus monkeys using recombinant adeno-associated type i viral vectors","volume":"27","author":"Conlon","year":"2016","journal-title":"Human Gene Therapy Clinical Develop"},{"issue":"9","key":"10.1016\/j.molmet.2024.101899_bib90","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.molmet.2024.101899_bib91","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jgm.1372","article-title":"Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression","volume":"11","author":"Sun","year":"2009","journal-title":"J\u00a0Gene Med"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib92","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1538-7836.2006.02220.x","article-title":"Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy","volume":"5","author":"Vandendriessche","year":"2007","journal-title":"J\u00a0Thromb Haemostasis"},{"issue":"2","key":"10.1016\/j.molmet.2024.101899_bib93","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/ijns6020031","article-title":"Newborn screening for pompe disease","volume":"6","author":"Sawada","year":"2020","journal-title":"Int J Neonatal Screening"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib94","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40478-015-0243-x","article-title":"Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease","volume":"3","author":"Schaaf","year":"2015","journal-title":"Acta Neuropathologica Commun"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib95","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40478-018-0620-3","article-title":"Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease","volume":"6","author":"Schaaf","year":"2018","journal-title":"Acta Neuropathologica Commun"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib96","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s40478-018-0609-y","article-title":"Satellite cells fail to contribute to muscle repair but are functional in Pompe disease (glycogenosis type II)","volume":"6","author":"Lagalice","year":"2018","journal-title":"Acta Neuropathologica Commun"},{"issue":"13","key":"10.1016\/j.molmet.2024.101899_bib97","doi-asserted-by":"crossref","first-page":"280","DOI":"10.21037\/atm.2019.04.48","article-title":"Restoring the regenerative balance in neuromuscular disorders: satellite cell activation as therapeutic target in Pompe disease","volume":"7","author":"Schaaf","year":"2019","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.molmet.2024.101899_bib98","doi-asserted-by":"crossref","DOI":"10.4081\/ejtm.2022.10064","article-title":"Involvement of muscle satellite cell dysfunction in neuromuscular disorders: expanding the portfolio of satellite cell-opathies","volume":"32","author":"Ganassi","year":"2022","journal-title":"Eur J Transl Myology"},{"key":"10.1016\/j.molmet.2024.101899_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.molmet.2024.101899_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in\u00a0vivo gene therapy with AAVs","author":"Mendell","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.molmet.2024.101899_bib101","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-021-00164-x","article-title":"Gene therapy community grapples with toxicity issues, as pipeline matures","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.molmet.2024.101899_bib102","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: an integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.molmet.2024.101899_bib103","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"15\u201316","key":"10.1016\/j.molmet.2024.101899_bib104","article-title":"Adeno-associated virus-induced dorsal root ganglion pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum Gene Ther"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877824000309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877824000309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:33:49Z","timestamp":1761957229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877824000309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":104,"alternative-id":["S2212877824000309"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2024.101899","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2024.101899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"101899"}}